{"id":406752,"date":"2025-08-29T00:30:00","date_gmt":"2025-08-28T22:30:00","guid":{"rendered":"https:\/\/medizinonline.com\/?p=406752"},"modified":"2025-08-28T22:19:08","modified_gmt":"2025-08-28T20:19:08","slug":"biologics-oral-peptide-and-trivalent-nanobody-current-results-and-trends","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/en\/biologics-oral-peptide-and-trivalent-nanobody-current-results-and-trends\/","title":{"rendered":"Biologics, oral peptide and trivalent nanobody &#8211; current results and trends"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Top-line results are available for both Icotrokinra and Sonelokimab, which attest to the great therapeutic potential of these innovative drug candidates. However, there is also extremely interesting new evidence from clinical trials and real-world settings for the currently approved monoclonal antibodies from the interleukin (IL)-23 and IL-17 inhibitor groups. In terms of personalized medicine, it is increasingly important to select a therapy option tailored to the respective conditions from the variety of treatment options.    <\/strong><\/p>\n\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/en\/my-account\/packages\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">Already a member? <a href=\"https:\/\/medizinonline.com\/en\/log-in\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Fen%2Fbiologics-oral-peptide-and-trivalent-nanobody-current-results-and-trends%2F\">Log in here<\/a><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>Top-line results are available for both Icotrokinra and Sonelokimab, which attest to the great therapeutic potential of these innovative drug candidates. However, there is also extremely interesting new evidence from&#8230;&hellip;... <\/p>\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/en\/my-account\/packages\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">Already a member? <a href=\"https:\/\/medizinonline.com\/en\/log-in\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Fen%2Fbiologics-oral-peptide-and-trivalent-nanobody-current-results-and-trends%2F\">Log in here<\/a><\/div><\/div><\/div>","protected":false},"author":7,"featured_media":406753,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"Psoriasis and PsA  ","footnotes":"[{\"content\":\"WHO-5: This is the WHO wellbeing index, where 0 means no wellbeing and 100 means maximum wellbeing (10 points is the threshold for a clinically relevant change).\",\"id\":\"0eb10af1-4631-44c6-b46a-a26d220fe05b\"},{\"content\":\"WPAI: the questionnaire on work productivity and activity impairment includes the areas of work absences, work in an impaired state (presenteeism), loss of work productivity and impairment of activity.\",\"id\":\"e80dbffb-1eb1-437f-9f1c-48d573f78cda\"},{\"content\":\"All patients received bimekizumab-bkzx every four weeks (q4w) until week 16 and then received either q4w or q8w depending on their response to treatment. If you receive q4w through week 16, q8w is the approved dosing regimen thereafter (q4w\\\/q8w). The results included patients who received both q4w\\\/q8w and q4w\\\/q4w.  \",\"id\":\"03b46733-3caf-4a5d-bf29-6aec9d08b811\"}]"},"category":[11548,11331,11513,11340,11480,11503],"tags":[27074,12391,18157,84534,84532,15729,14032,13387,26569,12536,84535,67738,84533,26999],"powerkit_post_featured":[],"class_list":["post-406752","post","type-post","status-publish","format-standard","has-post-thumbnail","category-rx-en","category-allergology-and-clinical-immunology","category-congress-reports","category-dermatology-and-venereology","category-rheumatology","category-studies","tag-bimekizumab-en","tag-biologics-en","tag-guselkumab-en","tag-icotrokinra-en","tag-oral-peptide","tag-psa-en","tag-psoriasis-en-2","tag-psoriatic-arthritis","tag-risankizumab-en","tag-secukinumab-en","tag-sonelokimab-en","tag-tildrakizumab-en","tag-trivalent-nanobody","tag-zdft-en","pmpro-level-required","pmpro-level-1","pmpro-no-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-07-13 15:58:43","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"en_US","wpml_translations":{"fr_FR":{"locale":"fr_FR","id":406746,"slug":"medicaments-biologiques-peptide-oral-et-nanobody-trivalent-resultats-et-tendances-actuels","post_title":"M\u00e9dicaments biologiques, peptide oral et nanobody trivalent - r\u00e9sultats et tendances actuels","href":"https:\/\/medizinonline.com\/fr\/medicaments-biologiques-peptide-oral-et-nanobody-trivalent-resultats-et-tendances-actuels\/"},"it_IT":{"locale":"it_IT","id":406743,"slug":"biologici-peptidi-orali-e-nano-corpi-trivalenti-risultati-e-tendenze-attuali","post_title":"Biologici, peptidi orali e nano-corpi trivalenti - risultati e tendenze attuali","href":"https:\/\/medizinonline.com\/it\/biologici-peptidi-orali-e-nano-corpi-trivalenti-risultati-e-tendenze-attuali\/"},"pt_PT":{"locale":"pt_PT","id":406749,"slug":"biologicos-peptidos-orais-e-nanocorpos-trivalentes-resultados-e-tendencias-actuais","post_title":"Biol\u00f3gicos, p\u00e9ptidos orais e nanocorpos trivalentes - resultados e tend\u00eancias actuais","href":"https:\/\/medizinonline.com\/pt-pt\/biologicos-peptidos-orais-e-nanocorpos-trivalentes-resultados-e-tendencias-actuais\/"},"es_ES":{"locale":"es_ES","id":406740,"slug":"biologicos-peptidos-orales-y-nanoanticuerpos-trivalentes-resultados-y-tendencias-actuales","post_title":"Biol\u00f3gicos, p\u00e9ptidos orales y nanoanticuerpos trivalentes: resultados y tendencias actuales","href":"https:\/\/medizinonline.com\/es\/biologicos-peptidos-orales-y-nanoanticuerpos-trivalentes-resultados-y-tendencias-actuales\/"}},"_links":{"self":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/406752","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/comments?post=406752"}],"version-history":[{"count":1,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/406752\/revisions"}],"predecessor-version":[{"id":406754,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/406752\/revisions\/406754"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/media\/406753"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/media?parent=406752"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/category?post=406752"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/tags?post=406752"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/powerkit_post_featured?post=406752"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}